Key facts
- It has raised $500K across 1 recorded rounds; the latest was Seed Round ($300K) in Mar 2025.
- Notable investors include Antler, BioTools Innovator, Atlas SGR.
- Amptiv Biosciences has filed 2 Form Ds with the SEC since 2024, most recently Apr 2025 ($300K sold to 3 investors).
- Status: Privately Held (backing).
Investors
3- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Amptiv Biosciences
Funding rounds
1 roundsAbout Amptiv Biosciences
Operator of a biotechnology company intended to build the future of mRNA therapeutics. The core platform uses a post-transcriptional chemical modification system that bypasses the legacy constraints of enzymatic mRNA production, enabling people to help in enzymatic production of mRNA by in vitro transcription, which severely constrains the diversity of chemical modifications
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2024
- Employees
- 4
- Website
- amptivbio.com/
- Ownership
- Privately Held (backing)
Amptiv Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amptiv Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amptiv Biosciences in its N-PORT filings yet. We sweep new filings monthly.